Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer (Q37728847)

22 August 2017

1 reference

title

Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer (English)

1 reference

22 August 2017

0 references

1 reference

Eleftherios P. Diamandis

series ordinal

3

1 reference

22 August 2017

Vathany Kulasingam

1

0 references

author name string

Maria P Pavlou

series ordinal

2

1 reference

PubMed ID

20383179

22 August 2017

language of work or name

English

0 references

publication date

12 April 2010

1 reference

22 August 2017

Nature Reviews Cancer

1 reference

22 August 2017

10

1 reference

22 August 2017

371-378

1 reference

22 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2831

22 August 2017

0 references

cites work

Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer

1 reference

Tissue proteomics for cancer biomarker development: laser microdissection and 2D-DIGE.

21 January 2018

1 reference

Maximizing mouse cancer models

21 January 2018

1 reference

21 January 2018

Cancer statistics, 2008

1 reference

Gene-expression profiling in epithelial ovarian cancer

31 March 2020

1 reference

31 March 2020

1 reference

Promising directions for the diagnosis and management of gynecological cancers

31 March 2020

1 reference

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

31 March 2020

1 reference

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts

31 March 2020

1 reference

An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.

31 March 2020

1 reference

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

31 March 2020

1 reference

Diagnostic markers for early detection of ovarian cancer

31 March 2020

1 reference

Phases of biomarker development for early detection of cancer

31 March 2020

1 reference

Lessons from controversy: ovarian cancer screening and serum proteomics.

31 March 2020

1 reference

Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design

31 March 2020

1 reference

Progress and challenges in screening for early detection of ovarian cancer

31 March 2020

1 reference

The human plasma proteome: history, character, and diagnostic prospects

31 March 2020

1 reference

Use of proteomic patterns in serum to identify ovarian cancer

31 March 2020

1 reference

Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis.

31 March 2020

1 reference

Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry

31 March 2020

1 reference

Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems.

31 March 2020

1 reference

Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations

31 March 2020

1 reference

SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics

31 March 2020

1 reference

The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?

31 March 2020

1 reference

Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer

31 March 2020

1 reference

Validation of Breast Cancer Biomarkers Identified by Mass Spectrometry

31 March 2020

1 reference

Neoplastic characteristics of the DNA found in the plasma of cancer patients

31 March 2020

1 reference

Malignant ascites: past, present, and future

31 March 2020

1 reference

Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited

31 March 2020

1 reference

A Proteome Resource of Ovarian Cancer Ascites: Integrated Proteomic and Bioinformatic Analyses To Identify Putative Biomarkers

31 March 2020

1 reference

Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future

31 March 2020

1 reference

Large-scale proteomics analysis of human ovarian cancer for biomarkers

31 March 2020

1 reference

Tissue culture-based breast cancer biomarker discovery platform

31 March 2020

1 reference

Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains

31 March 2020

1 reference

A mouse model repository for cancer biomarker discovery

31 March 2020

1 reference

Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers

31 March 2020

1 reference

Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.

31 March 2020

1 reference

Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy

31 March 2020

1 reference

Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum

31 March 2020

1 reference

Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research

31 March 2020

1 reference

Gene expression signature with independent prognostic significance in epithelial ovarian cancer

31 March 2020

1 reference

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

31 March 2020

1 reference

Modelling breast cancer: one size does not fit all.

31 March 2020

1 reference

Protein biomarker discovery and validation: the long and uncertain path to clinical utility

31 March 2020

1 reference

Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers

31 March 2020

1 reference

Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer

31 March 2020

1 reference

Nidogen-2: a new serum biomarker for ovarian cancer

31 March 2020

1 reference

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

31 March 2020

1 reference

Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.

31 March 2020

1 reference

Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis

31 March 2020

1 reference

The granulin-epithelin precursor: a putative new growth factor for ovarian cancer

31 March 2020

1 reference

Proteomics-driven cancer biomarker discovery: looking to the future.

31 March 2020

1 reference

Protein quantification by mass spectrometry: is it ready for prime time?

31 March 2020

1 reference

Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma

31 March 2020

1 reference

Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer

31 March 2020

1 reference

12 December 2020

Validation of candidate serum ovarian cancer biomarkers for early detection

1 reference

12 December 2020

The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

1 reference

12 December 2020

The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC2831

1 reference

PubMed ID

20383179

Dimensions Publication ID

22 August 2017

0 references

1 reference

PubMed ID

20383179